Sanofi to buy Dynavax for US$2.2 billion to add shingles vaccine

Sanofi agreed to buy Dynavax Technologies for about US$2.2 billion to expand its vaccines business with a shot for hepatitis B and an experimental shingles inoculation.

Sanofi will pay US$15.50 a share in cash for the Emeryville, California-based company, according to a statement on Wednesday (Dec 24). The price is 39% above Tuesday’s closing level for Dynavax.

The agreement isn’t expected to have any impact on Sanofi’s financial guidance for 2025, the company said. The company expects to complete the acquisition in the first quarter of 2026. BLOOMBERG

Decoding Asia newsletter: your guide to navigating Asia in a new global order. Sign up here to get Decoding Asia newsletter. Delivered to your inbox. Free.